Report cover image

End Stage Renal Disease Industry Research Report 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 132 Pages
SKU # APRC20351883

Description

Summary

According to APO Research, The global End Stage Renal Disease market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for End Stage Renal Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for End Stage Renal Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for End Stage Renal Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of End Stage Renal Disease include Newsol, Baxter, Guangdong Biolight, B. Braun, DaVita, Fresenius, Jafron Biomedical, Medtronic and Mayo Clinic, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for End Stage Renal Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding End Stage Renal Disease.
The End Stage Renal Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global End Stage Renal Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

End Stage Renal Disease Segment by Company

Newsol
Baxter
Guangdong Biolight
B. Braun
DaVita
Fresenius
Jafron Biomedical
Medtronic
Mayo Clinic
Nipro
Nikkiso
Sanxin Medtec
SWS Hemodialysis Care
Tianyi Medical
WEGO
Asahi Kasei
End Stage Renal Disease Segment by Type

Hemodialysis
Kidney Transplantation
Peritoneal Dialysis
End Stage Renal Disease Segment by Application

At Homes
Kidney Dialysis Centers
Hospitals
Others
End Stage Renal Disease Segment by Application

At Homes
Kidney Dialysis Centers
Hospitals
Others
End Stage Renal Disease Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global End Stage Renal Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of End Stage Renal Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of End Stage Renal Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of End Stage Renal Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Table of Contents

132 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 End Stage Renal Disease by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Hemodialysis
2.2.3 Kidney Transplantation
2.2.4 Peritoneal Dialysis
2.3 End Stage Renal Disease by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 At Homes
2.3.3 Kidney Dialysis Centers
2.3.4 Hospitals
2.3.5 Others
2.4 Assumptions and Limitations
3 End Stage Renal Disease Breakdown Data by Type
3.1 Global End Stage Renal Disease Historic Market Size by Type (2020-2025)
3.2 Global End Stage Renal Disease Forecasted Market Size by Type (2026-2031)
4 End Stage Renal Disease Breakdown Data by Application
4.1 Global End Stage Renal Disease Historic Market Size by Application (2020-2025)
4.2 Global End Stage Renal Disease Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global End Stage Renal Disease Market Perspective (2020-2031)
5.2 Global End Stage Renal Disease Growth Trends by Region
5.2.1 Global End Stage Renal Disease Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 End Stage Renal Disease Historic Market Size by Region (2020-2025)
5.2.3 End Stage Renal Disease Forecasted Market Size by Region (2026-2031)
5.3 End Stage Renal Disease Market Dynamics
5.3.1 End Stage Renal Disease Industry Trends
5.3.2 End Stage Renal Disease Market Drivers
5.3.3 End Stage Renal Disease Market Challenges
5.3.4 End Stage Renal Disease Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top End Stage Renal Disease Players by Revenue
6.1.1 Global Top End Stage Renal Disease Players by Revenue (2020-2025)
6.1.2 Global End Stage Renal Disease Revenue Market Share by Players (2020-2025)
6.2 Global End Stage Renal Disease Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of End Stage Renal Disease Head Office and Area Served
6.4 Global End Stage Renal Disease Players, Product Type & Application
6.5 Global End Stage Renal Disease Manufacturers Established Date
6.6 Global End Stage Renal Disease Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America End Stage Renal Disease Market Size (2020-2031)
7.2 North America End Stage Renal Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America End Stage Renal Disease Market Size by Country (2020-2025)
7.4 North America End Stage Renal Disease Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe End Stage Renal Disease Market Size (2020-2031)
8.2 Europe End Stage Renal Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe End Stage Renal Disease Market Size by Country (2020-2025)
8.4 Europe End Stage Renal Disease Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific End Stage Renal Disease Market Size (2020-2031)
9.2 Asia-Pacific End Stage Renal Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific End Stage Renal Disease Market Size by Country (2020-2025)
9.4 Asia-Pacific End Stage Renal Disease Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America End Stage Renal Disease Market Size (2020-2031)
10.2 South America End Stage Renal Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America End Stage Renal Disease Market Size by Country (2020-2025)
10.4 South America End Stage Renal Disease Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa End Stage Renal Disease Market Size (2020-2031)
11.2 Middle East & Africa End Stage Renal Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa End Stage Renal Disease Market Size by Country (2020-2025)
11.4 Middle East & Africa End Stage Renal Disease Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Newsol
12.1.1 Newsol Company Information
12.1.2 Newsol Business Overview
12.1.3 Newsol Revenue in End Stage Renal Disease Business (2020-2025)
12.1.4 Newsol End Stage Renal Disease Product Portfolio
12.1.5 Newsol Recent Developments
12.2 Baxter
12.2.1 Baxter Company Information
12.2.2 Baxter Business Overview
12.2.3 Baxter Revenue in End Stage Renal Disease Business (2020-2025)
12.2.4 Baxter End Stage Renal Disease Product Portfolio
12.2.5 Baxter Recent Developments
12.3 Guangdong Biolight
12.3.1 Guangdong Biolight Company Information
12.3.2 Guangdong Biolight Business Overview
12.3.3 Guangdong Biolight Revenue in End Stage Renal Disease Business (2020-2025)
12.3.4 Guangdong Biolight End Stage Renal Disease Product Portfolio
12.3.5 Guangdong Biolight Recent Developments
12.4 B. Braun
12.4.1 B. Braun Company Information
12.4.2 B. Braun Business Overview
12.4.3 B. Braun Revenue in End Stage Renal Disease Business (2020-2025)
12.4.4 B. Braun End Stage Renal Disease Product Portfolio
12.4.5 B. Braun Recent Developments
12.5 DaVita
12.5.1 DaVita Company Information
12.5.2 DaVita Business Overview
12.5.3 DaVita Revenue in End Stage Renal Disease Business (2020-2025)
12.5.4 DaVita End Stage Renal Disease Product Portfolio
12.5.5 DaVita Recent Developments
12.6 Fresenius
12.6.1 Fresenius Company Information
12.6.2 Fresenius Business Overview
12.6.3 Fresenius Revenue in End Stage Renal Disease Business (2020-2025)
12.6.4 Fresenius End Stage Renal Disease Product Portfolio
12.6.5 Fresenius Recent Developments
12.7 Jafron Biomedical
12.7.1 Jafron Biomedical Company Information
12.7.2 Jafron Biomedical Business Overview
12.7.3 Jafron Biomedical Revenue in End Stage Renal Disease Business (2020-2025)
12.7.4 Jafron Biomedical End Stage Renal Disease Product Portfolio
12.7.5 Jafron Biomedical Recent Developments
12.8 Medtronic
12.8.1 Medtronic Company Information
12.8.2 Medtronic Business Overview
12.8.3 Medtronic Revenue in End Stage Renal Disease Business (2020-2025)
12.8.4 Medtronic End Stage Renal Disease Product Portfolio
12.8.5 Medtronic Recent Developments
12.9 Mayo Clinic
12.9.1 Mayo Clinic Company Information
12.9.2 Mayo Clinic Business Overview
12.9.3 Mayo Clinic Revenue in End Stage Renal Disease Business (2020-2025)
12.9.4 Mayo Clinic End Stage Renal Disease Product Portfolio
12.9.5 Mayo Clinic Recent Developments
12.10 Nipro
12.10.1 Nipro Company Information
12.10.2 Nipro Business Overview
12.10.3 Nipro Revenue in End Stage Renal Disease Business (2020-2025)
12.10.4 Nipro End Stage Renal Disease Product Portfolio
12.10.5 Nipro Recent Developments
12.11 Nikkiso
12.11.1 Nikkiso Company Information
12.11.2 Nikkiso Business Overview
12.11.3 Nikkiso Revenue in End Stage Renal Disease Business (2020-2025)
12.11.4 Nikkiso End Stage Renal Disease Product Portfolio
12.11.5 Nikkiso Recent Developments
12.12 Sanxin Medtec
12.12.1 Sanxin Medtec Company Information
12.12.2 Sanxin Medtec Business Overview
12.12.3 Sanxin Medtec Revenue in End Stage Renal Disease Business (2020-2025)
12.12.4 Sanxin Medtec End Stage Renal Disease Product Portfolio
12.12.5 Sanxin Medtec Recent Developments
12.13 SWS Hemodialysis Care
12.13.1 SWS Hemodialysis Care Company Information
12.13.2 SWS Hemodialysis Care Business Overview
12.13.3 SWS Hemodialysis Care Revenue in End Stage Renal Disease Business (2020-2025)
12.13.4 SWS Hemodialysis Care End Stage Renal Disease Product Portfolio
12.13.5 SWS Hemodialysis Care Recent Developments
12.14 Tianyi Medical
12.14.1 Tianyi Medical Company Information
12.14.2 Tianyi Medical Business Overview
12.14.3 Tianyi Medical Revenue in End Stage Renal Disease Business (2020-2025)
12.14.4 Tianyi Medical End Stage Renal Disease Product Portfolio
12.14.5 Tianyi Medical Recent Developments
12.15 WEGO
12.15.1 WEGO Company Information
12.15.2 WEGO Business Overview
12.15.3 WEGO Revenue in End Stage Renal Disease Business (2020-2025)
12.15.4 WEGO End Stage Renal Disease Product Portfolio
12.15.5 WEGO Recent Developments
12.16 Asahi Kasei
12.16.1 Asahi Kasei Company Information
12.16.2 Asahi Kasei Business Overview
12.16.3 Asahi Kasei Revenue in End Stage Renal Disease Business (2020-2025)
12.16.4 Asahi Kasei End Stage Renal Disease Product Portfolio
12.16.5 Asahi Kasei Recent Developments
13 Report Conclusion
14 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.